Medicine


Showing 981-1,000 of 2,393 Results

  • Masataka Kawana

    Masataka Kawana

    Assistant Professor of Medicine (Cardiovascular Medicine)

    BioDr. Kawana joined the Advanced Heart Failure and Transplant Cardiology group in 2018. He completed his internal medicine, cardiovascular medicine, and heart failure training at Stanford. He also completed a postdoctoral research fellowship under Dr. James Spudich in the Department of Biochemistry. He is the Medical Director of Ambulatory Heart Failure and Cardiomyopathy Service in the Advanced Heart Failure program. He manages advanced heart failure patients in the clinic, CCU/heart failure service, and post-heart transplant/MCS service. His research interests are in the fundamental mechanism of inherited cardiomyopathies, and he studies the effect of gene mutation on the cardiac sarcomere function using cutting-edge biochemical and biophysical approaches, which would lead to the development of novel pharmacotherapy that directly modulates cardiac muscle protein. He is involved in multiple clinical trials for pharmacotherapy and novel device studies in heart failure and inherited cardiomyopathy.

  • Vanessa Kennedy

    Vanessa Kennedy

    Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    BioDr. Kennedy is a board-certified hematologist and medical oncologist who specializes in the treatment of myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myelofibrosis (MF). She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine.

    Dr. Kennedy's research focuses on the use of clinical informatics and bioinformatics in understanding cancer biology and improving patient outcomes. She is also actively involved in interventional clinical trials. Her work has been supported by grant funding from the American Society of Clinical Oncology, the American Society of Hematology, and the Chan-Zuckerberg Foundation.

  • Rachel Keranen

    Rachel Keranen

    Casual - Non-Exempt, Medicine

    Current Role at StanfordExecutive and strategic communications for the Department of Medicine.

  • Andreas Kerschbaumer

    Andreas Kerschbaumer

    Postdoctoral Scholar, Immunology and Rheumatology

    BioDr. Andreas Kerschbaumer is a postdoctoral scholar in the Division of Immunology and Rheumatology at Stanford University, conducting research in the Robinson and Khatri Labs. His work integrates clinical rheumatology with computational and systems immunology, applying meta-analytic techniques on transcriptomic datasets to uncover mechanisms of autoimmunity and improve therapeutic strategies in rheumatology.

    He trained in internal medicine and rheumatology at the Medical University of Vienna, Department of Medicine III, Division of Rheumatology, where he also completed his PhD under Professors Smolen and Aletaha on treatment outcomes in inflammatory arthritis, followed by his habilitation on strategies to optimize the interpretation of clinical trial data in rheumatoid and psoriatic arthritis.

    Dr. Kerschbaumer has been actively engaged with the European Alliance of Associations for Rheumatology (EULAR), contributing as Fellow, Methodologist, and Co-Methodologist to multiple international taskforces, including the 2019, 2022, and 2025 rheumatoid arthritis recommendations and the 2019 and 2023 psoriatic arthritis recommendations. He is currently a member of the EULAR Quality of Care Committee and serves as Co-Abstract Chair of the ACR Rheumatoid Arthritis abstract committee.

  • Kian Keyashian

    Kian Keyashian

    Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

    BioThe management of inflammatory bowel disease continues to evolve, with the introduction of biologic and small molecule therapies and new goals of treatment, with an emphasis on healing the bowel. My career goal since my graduation from IBD fellowship in 2012 has been to improve the outcomes and quality of life of patients with inflammatory bowel disease. In line with these goals, my research has focused investigating new noninvasive diagnostic test, finding factors early in the disease course that might predict a more aggressive disease course and need for different therapies, and investigating new promising effective medications with less side effects.

  • Ali Raza Khaki, MD

    Ali Raza Khaki, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.

    In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
    With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.

    His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He is the site principal investigator for multiple clinical trails investigating new therapies for genitourinary cancers.

    Dr. Khaki is also active working clinically in inpatient oncology and is a Unit Based Medical Director for G1, an oncology hospital unit and is the Director of Inpatient Oncology. In this role, he oversees the inpatient oncology teams, works closely with the cancer center to develop new transitions of care pathways from inpatient to outpatient and has co-led an inpatient oncology research group to study quality improvement, care delivery and end-of-life care for patients with cancer.

    Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.

    He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers.

  • Saad A. Khan, MD

    Saad A. Khan, MD

    Associate Professor of Medicine (Oncology)

    BioDr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.

    Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.

    Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.

    He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.

    Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.

    Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.

    He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.

    When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach.

  • Abha Khandelwal

    Abha Khandelwal

    Clinical Professor, Medicine - Cardiovascular Medicine

    Current Research and Scholarly InterestsCardiovascular disease in Pregnancy
    Valvular Heart Disease
    Cardiomyopathy
    Pericardial disease
    Heart Disease in South Asians
    Women's Cardiovascular Disease